Heart failure is a major health problem in developed countries. As a result of the increased prevalence of hypertension, diabetes mellitus, and chronic renal failure and the improved initial survival of patients with acute myocardial infarction or chronic ischemic heart disease, the prevalence of heart failure is continuously increasing. Therefore, the socioeconomic burden of controlling heart failure in developed countries is steeply increasing as well. Even with advanced treatment options, e.g., pharmacotherapy including betaadrenergic blocking agents, renin-angiotensin system blockers, mechanical cardiac assist devices, cardiac resynchronization therapy, and finally, cardiac transplantation, the 5-year survival rate of advanced heart failure is still about 50%. Other than the above classic treatment modalities in heart failure, cell or gene therapy has been recommended as a new, investigational treatment option for this disease. With increasing knowledge about the molecular and genetic mechanisms of heart failure, gene delivering systems, and the development of biocompatible biomaterial gene transfection molecules, gene therapy has fabulous academic interest for treating chronic, advanced, non-optional heart failure patients.
Introduction
Heart failure (HF) is a clinical syndrome that occurs in patients who, because of an inherited or acquired abnormality of cardiac structure or function, develop a constellation of clinical symptoms (dyspnea and fatigue) and signs (edema and rales) that lead to frequent hospitalization, a poor quality of life, and a shortened life expectancy. 1 General methods of GT using intracellular Ca 2+ handling for heart failure are depicted. 7 The purpose of this article is to supply some knowledge about GT as a potential treatment for HF. In this review, we attempt to explain the mechanism and usefulness of the GTs that are related to calcium handling in the cardiomyocytes (CMCs) in the HF. (SERCA2a), an intracoronary catheter-based gene delivery method was used. 8 
Intraventricular delivery
The most global and efficient gene delivery method in a preclinical, small animal HF model is the intraventricular injection via the apical myocardium to the aortic root with aortic and pulmonary artery clamping for 10∼40 seconds. 9 Gene spreading to the entire myocardium with this method is very efficient compared with other delivery methods. This method could be applied to human subjects with HF in a limited manner under the cardiopulmonary bypass applied for other conditions, e.g., coronary bypass or open heart surgery.
Retroperfusion via the coronary sinus
Catheterization into a coronary sinus or subselective cardiac vein under the concurrent occlusion of outflow from the coronary sinus distributes the transgene in a retrograde fashion from the coronary venous circulation through the capillary bed to the CMC and interstitium in potentially all regions of the myocardium. 10 Compared with intramyocardial injection, this method results in more homogeneous transmural gene expression. 10 
Intramyocardial direct injection
Direct injection of the genetic material into a myocardium can be done under beating heart surgery or cardioplegia with cardiac bypass with thoracotomy. Local expression and invasiveness limit its use. Moreover, the needle track in the myocardium can be an arrhythmogenic focus. To overcome these limitations of myocardial gene injection, catheter-based endomyocardial gene injection using a nonfluoroscopic, three-dimensional mapping and injection (NOGA) system has been applied in the clinical field. This method was also adopted in the study of Adenovirus (Adv)-Vascular Endothelial Growth Factor (VEGF)121 GT for non-optional CAD and some stem cell injection for HF. 11 Even with the use of endomyocardial catheter-based gene delivery, however, local expression of genetic material is a big disadvantage of this method, especially in patients with global ventricular dysfunction.
Intrapericardial gene delivery
After the injection of genetic material into the pericardial space, 25% of it is recovered in the myocardium. To elevate myocardial transfer efficiency, a thermosensitive gel/plasmid DNA mixture can be used.
This formulation improves retention time at the site of injection and enhances myocardial delivery efficiency with low cytotoxicity compared with a PEI/DNA mixture. 12 This method can be applied to humans with a small thoracotomy or video-assist thoracostomy.
Percutaneous cardiac recirculation-mediated gene transfer
Recirculating perfusate delivery was achieved with the use of a novel cardiac perfusion circuit in this method. 13 Under fluoroscopic guidance, coronary venous blood is recaptured from the coronary sinus with the use of a percutaneously positioned occlusive balloon recovery catheter. The draining catheter is placed in such a position to exclude the azygous vein, either by occluding it with the balloon or by incorporating a structural element beyond the catheter to prevent dynamic collapse during the application of suction.
Venous return is facilitated by the use of a roller pump, followed by reoxygenation with an oxygenator membrane.
The oxygenated perfusate is then directed to the left coronary territory via a nonocclusive catheter placed percutaneously in the left main coronary artery. To determine the distribution of the myocardial perfusate delivered in this manner, we characterized the pattern of delivery of the fluorophore indocyanine green (ICG) in 10 milliliters of circuit recirculated for 10 min. The heart was then explanted and examined by using near-infrared spectroscopy.
Promising gene therapy molecular targets for heart failure and a blunted response to β-adrenergic stimulation. 22 In rats with cardiac dysfunction due to MI, the AAVantisense PLN gene delivery to the myocardium around the MI effectively attenuated the depression of cardiac dysfunction, significantly inhibited PLN expression, and enhanced myocardial SERCA acitivity. 23 Tsuji et al. This phenomenon was originated from a profound abnormal cytosolic Ca 2+ transient and a reduced phos-phorylation of PLN after TAC in transgenic mice. 29 According to the above data, GT targeted to PP1 or IP expression, which induces SERCA2a activity boosting, could be good strategy in HF in the future.
Parvalbumin (PV)
PV is an acidic, intracellular Ca 2+ binding protein of low molecular weight. It is associated with several Ca 2+mediated cellular activities and physiologic responses. 33 Further investigation of physiologic responses along with PV expression and tissue level in an optimal HF animal model and human CMCs is essential to apply these potentially beneficial findings to human HF.
PV may function as a "Ca
6. S100A1 S100A1, a Ca 2+ -binding protein of the EF-hand type, is preferentially expressed in the healthy heart and has been identified as a positive inotropic regulator of in vivo and in vitro myocardial contractility with cardioprotective actions at least in vitro. S100A1 undergoes a large conformational change upon binding Ca 2+ as necessary to interact with numerous protein targets.
Targets of S100A1 include proteins involved in Ca 2+ signaling (RyR, SERCA2a, PLN) and Ca 2+ -activated proteins (annexin V/VI, S100B, S100A4, A100P, and F1 ATP synthase). 34 S100A1 expression levels in myocardial tissue are significantly down-regulated in endstage HF. Intracoronary delivery of the human S100A1 gene by the use of a first-generation Adv normalized the diminished S100A1 protein abundance in a rat HF model that in turn rescued both impaired contractile performance and Ca 2+ cycling of the failing myocardium. 35 Adv-S100A1 gene delivery into rat CMCs increased fractional shortening by 55% and systolic Ca 2+ amplitudes by 62%, whereas S100A1 protein increased SERCA activity by 28%. The gain in systolic Ca 2+ supply was not only seen during basal conditions but also with isoproterenol-stimulated Ca 2+ cycling. Thus, S100A1 enhances cardiac contractility by increasing intracellular Ca 2+ fluxes at least in part due to a modulation of SERCA. 36 above result was confirmed with transgenic overexpression of the S100A1 in mouse.
Contractile function and Ca 2+ handling properties were Small insert capacity Difficulty in high viral stock production Low transfectionefficiency into non-dividing cells Safety concern, low viral titer Safety concern Difficulty in high viral stock production Non-viral Naked DNA, plasmid DNA Nanoparticle Easy production, low toxicity Easy production, low toxicity Real time trackability in ORMOSIL Low efficiency of transfection Low efficiency of transfection Short duration of expression increased in ventricular myocytes isolated from S100A1 transgenic mice. Enhanced cellular Ca 2+ cycling by S100A1 was associated both with increased SR Ca 2+ content and with enhanced SR Ca 2+ -induced Ca 2+ release, and S100A1 was shown to be associated with the cardiac RyR. 37 AAV6-S100A1 delivery with aortic root injection under ascending aortic clamping showed improved SR Ca 2+ handling, including improved contractile function and LV remodeling in rat HF. 38 The use of S100A1 as a therapeutic target is actually not restricted to cardiac GT but could be employed in the emerging fields of cardiac tissue engineering and cellbased therapy. Engineered heart tissue from rat CMCs showed enhanced contractile performance at baseline and in response to β-adrenergic receptor stimulation after S100A1 gene addition, indicating that S100A1based genetic manipulation might be a promising strategy to strengthen the therapeutic effectiveness of artificial cardiac tissue or even artificial hearts. 39 Further evidence gathering from large animal HF models with S100A1
GT is essential to apply this potential therapeutic molecule to human HF.
Gene transfer vectors
Both viral and non-viral vector systems are available.
But, there is no exist one vector system meets all the various criteria, e.g., ease of preparing, excellent gene transfection efficiency, durable gene expression, and noninflammatory and nonimmunogenic properties. Recently, a non-viral vector system has been under investigation to improve gene transfection efficiency with low immunogenicity. The major vector systems are summarized in Table 1 .
Adenoviral (Adv) vector
The Adv vector is the most commonly applied vector in preclinical HF models because of its high gene transfer efficiency into nondividing cells like CMCs.
The disadvantages of the Adv vector are its relatively short duration of gene expression (3∼4 weeks), neutralizing antibody induction (which is related to a reduction of gene expression in the case of repeated injection), immunogenicity, and precipitation of cellular apoptosis or necrosis. 40 The new-generation Adv vectors shows longer gene expression and reduced immunogenicity. 40 
Adeno-associated virus (AAV) vector
AAV vectors effectively transfer genetic material to both dividing and nondividing cells and they integrate into the genome of the host cell and support durable transgenic expression for about 30 weeks. 41 However, it is very difficult to generate a purified high viral titer with an AAV vector and its packaging capability is less than 4.7 kilobases. 42 
Retroviral and lentiviral vectors
Retroviral vectors are less immunogenic and their transfection efficiency is good in dividing cells in vitro.
Long-term genetic expression is guaranteed, but transfection efficiency to nondividing cells is very low. The lentiviral vector may achieve efficient expression in nondividing cells or beating cells like CMCs. occur either in a random manner or upon binding to a specific receptor depending on the design of conjugates. 44 A controlled-release DNA-polymer coating delivery system has been investigated for transfection of cardiac tissue. 45 Recently, synthetic nonviral materials are fast gaining popularity as safe and efficient vectors for delivering genes to target organs. Not only can nanoparticles function as efficient gene carriers, they also can simultaneously carry diagnostic probes for direct "real-time" visualization of gene transfer and downstream process. 46 For example, ORMOSIL (organically modified silica) nanoparticles can condense, protect, and deliver plasmid DNA within cells. This nanoparticle was effectively used in mouse brain tissue with stereotactic surgery. 47 
